Engineered RBC Metabolic Pathway for GAMT Deficiency Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for Guanidinoacetate Methyltransferase (GAMT) deficiency, such as high-dose creatine supplementation, suffer from poor patient compliance due to strict adherence requirements, and there is a need for a more effective therapeutic approach to manage the accumulation of toxic guanidinoacetate and restore creatine levels.

Innovation Solution

Engineering red blood cells (RBCs) with recombinant guanidinoacetate methyltransferase (GAMT) and methionine adenosyltransferase (MAT) proteins to catalyze the conversion of guanidinoacetate into creatine, utilizing a novel metabolic pathway that degrades toxic guanidinoacetate and produces creatine, maintaining RBC functionality.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If high-dose creatine supplementation is used to treat GAMT deficiency, then creatine levels increase, but patient compliance deteriorates due to strict adherence requirements

Engineering Contradiction:

Improvecreatine levelsVSAvoidpatient compliance

Core Design Contradiction:

Quantity of substanceVSEase of operation

Solution Approach 1:

The engineered red blood cells perform the therapeutic function autonomously within the patient's body. The cells continuously convert guanidinoacetate to creatine without requiring external supplementation or patient adherence to dosing schedules, thereby eliminating the compliance issue while maintaining elevated creatine levels

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent replaces the mechanical system of oral supplementation (requiring patient action) with a biological system (engineered cells performing enzymatic conversion). The enzymatic reaction occurs automatically within the circulatory system, substituting the need for mechanical ingestion and adherence with passive physiological function

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If conventional enzyme replacement therapy is used, then GAMT deficiency is addressed, but the metabolic pathway remains incomplete and toxic metabolites accumulate

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtoxic metabolite accumulation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent merges two enzymatic functions into a single therapeutic cell system: GAMT activity to convert guanidinoacetate to creatine, and MAT activity to regenerate S-adenosylmethionine from methionine. This combination creates a self-sustaining metabolic pathway that continuously produces creatine while consuming the toxic substrate, eliminating harmful metabolite accumulation

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The engineered red blood cells perform multiple functions simultaneously: they catalyze the conversion of guanidinoacetate to creatine, regenerate methionine from homocysteine via MAT, and maintain normal RBC physiology. This multi-functionality ensures complete metabolic pathway coverage without requiring separate therapeutic agents for each step

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The engineered RBCs effectively degrade guanidinoacetate and produce creatine, addressing the deficiency by maintaining normal creatine levels and avoiding toxic accumulation, providing a potential treatment for GAMT deficiency and related conditions.

Implementation Method 1

modified for catalyzing the conversion of guanidinoacetate acid (GAA) into creatine in the presence of glucose and methionine using an exogenous guanidinoacetate methyltransferase (GAMT) and methionine adenosyltransferase (MAT) protein

Methodology Applied

Scientific EffectEnzyme catalysis: Enzyme

Implementation Method 2

These two enzymes, collectively, activate a new metabolic pathway that permits said isolated cells, such as red blood cells (RBCs) to catabolize GAA with the simultaneous formation of creatine

Methodology Applied

Scientific EffectCatalysis: Catalysis

Data Source

PatentUS20250340852A1Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine

Publication Date: 2025.11.06 QUINCE THERAPEUTICS INC

AI summary

The present invention relates to an isolated cell modified for catalyzing the conversion of guanidinoacetate acid (GAA) into creatine in the presence of glucose and methionine using an exogenous guanidinoacetate methyltransferase (GAMT) and methionine adenosyltransferase (MAT) protein, a pharmaceutical composition comprising a plurality of said isolated cells and uses thereof.